NCT02612194View on ClinicalTrials.gov

LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

September 27, 2016

Primary Completion Date

September 17, 2019

Study Completion Date

November 21, 2019

Conditions
Urinary Bladder NeoplasmsUreteral NeoplasmsUrethral Neoplasms
Interventions
DRUG

Crizotinib

Crizotinib was administered orally at 250mg twice daily

Trial Locations (1)

28204

Levine Cancer Institute, Charlotte

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Wake Forest University Health Sciences

OTHER

NCT02612194 - LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer | Biotech Hunter | Biotech Hunter